Interest in studying the biology of LRRK2 (leucine-rich repeat kinase 2) started in 2004 when missense mutations in the LRRK2 gene were linked to an inherited form of Parkinson's disease with clinical and pathological presentation resembling the sporadic syndrome. LRRK2 is a complex molecule containing domains implicated in protein interactions, as well as kinase and GTPase activities. The observation that the common G2019S mutation increases kinase activity in vitro suggests that altered phosphorylation of LRRK2 targets may have pathological outcomes. Given that protein kinases are ideal targets for drug therapies, much effort has been directed at understanding the role of LRRK2 kinase activity on disease onset. However, no clear physiological substrates have been identified to date, indicating that much research is still needed to fully understand the signalling pathways orchestrated by LRRK2 and deregulated under pathological conditions.
Introduction
PD (Parkinson's disease) is a usually sporadic late-onset disorder that affects an increasing number of people in aging populations. The precise causes of the disease are still uncertain, but it is clear that both genetic and environmental factors contribute to disease onset (reviewed in [1] ). In the last 15 years, a number of loci associated with Mendelian forms of PD have been identified, and mutations in at least five genes with both recessive and dominant modes of inheritance are clearly linked to familiar forms of PD (reviewed in [2] ). Back in 2002, Funayama et al. [3] identified a novel PD locus termed PARK8 in a large Japanese kindred affected by an autosomal form of PD resembling the idiopathic syndrome. A couple of years later, two independent collaborations not only reported additional families from North America and Europe (English and Spanish of Basque descent) affected by inherited PD with mutations in PARK8, but also discovered that the gene responsible for the disease was LRRK2 (leucinerich repeat kinase 2) [4, 5] . The protein encoded by the LRRK2 gene is a large, 286 kDa, molecule that was initially named 'dardarin' from the word 'dardara' which in Basque language means tremor, a typical feature of PD [4] . At that time, there was no clue as to the biological function of LRRK2 and the pioneering research started with the far from trivial cloning of the 7527 nucleotides constituting the open reading frame of LRRK2, to undertake the first biochemical characterization of the protein and to assess the effects of PD-linked mutations in cell models. LRRK2 belongs to the ROCO family of proteins which are characterized by the presence of a conserved ROC (Ras of complex proteins) and COR (C-terminal of ROC) bidomain [6] . LRRK2 also contains a kinase domain C-terminal to ROC-COR, as well as several putative protein-protein and protein-lipid interaction domains (Figure 1 ).
Since 2004, the kinase activity of LRRK2 has been scrutinized extensively, with particular emphasis on the effects of pathological mutations, the relationship between kinase and GTPase activities and the potential heterologous targets of kinase activity. The present review discusses the current knowledge of LRRK2 kinase activity and the experimental evidence on its contribution to PD pathogenesis. Also discussed is whether inhibiting LRRK2 kinase activity may be beneficial to counteract its purported pathological effects.
LRRK2 autophosphorylation: a red herring?
It has been shown that LRRK2 is capable of undergoing efficient autophosphorylation when incubated in a test tube in the presence of ATP and Mg 2 + (reviewed in [7, 8] ). This property has been used extensively as proxy to assess the activity of wild-type compared with mutant proteins in vitro until more efficient model substrates such as LRRKtide or Nictide have been described [9, 10] . Using autophosphorylation as a readout of kinase activity, independent groups have tested the effects of pathological mutations on this activity, and there is general agreement that only the common G2019S mutation placed in the activation loop of the kinase domain robustly increases kinase activity, whereas other mutations do not display a clear effect (reviewed in [7] ). It has been suggested that LRRK2 is a dimeric protein [11] [12] [13] and autophosphorylation appears to be an intra-dimeric event [12] . Moreover, LRRK2 can phosphorylate itself only in the presence of an intact C-terminus [9, 12] , whereas the N-terminal portion of the protein seems to act as an inhibitory element [9, 12, 14] . These observations suggest a fine intramolecular regulation of the kinase activity and also the possible existence of indispensable interacting heterologous elements (e.g. proteins or lipids) at the C-terminus. One important question is whether autophosphorylation is a physiologically relevant process occurring in the cell or only an in vitro artefact. Several independent groups have mapped LRRK2 autophosphorylation sites and found that the majority of them are located within the ROC domain [15] [16] [17] [18] [19] (Figure 2 ). Of these residues, Thr 1410 , Thr 1491 and Thr 1503 have been reported to be phosphorylated by at least three independent groups [15] [16] [17] [18] [19] . However, these phosphorylation residues were identified upon in vitro autophosphorylation, whereas phosphorylation-specific antibodies against phospho-Thr 1503 [19] or phospho-Thr 1964 in the kinase domain [17] failed to recognize phospho-LRRK2 from cell lysates unless in vitro phosphorylation was performed. In fact, although LRRK2 is basally phosphorylated at different sites in the N-terminal region [15] , none of these sites is the outcome of its autokinase activity. One possible explanation is that specific stimuli are needed to trigger autophosphorylation, which is otherwise undetectable under basal conditions. The serine/threonine kinase domain of LRRK2 exhibits similarity with the RIPK (receptor-interacting protein kinase) family that plays critical roles in cellular stress responses [20] and it has also been linked to stress response through interaction with MKKs (mitogen-activated protein kinase kinases) and JIPs [JNK (c-Jun N-terminal kinase)-interacting proteins] [21, 22] . It is therefore possible that LRRK2 undergoes activation through autophosphorylation in response to stress.
The observation that autophosphorylation sites are mainly clustered within the ROC domain where the other enzymatic activity of LRRK2 is present suggests the intriguing possibility that autophosphorylation is an intramolecular post-translational modification that regulates the rate of GTP hydrolysis. In this scenario, the GTPase activity would be the output of LRRK2 biological function with the kinase activity serving as an intramolecular modulator of the ROC domain that tunes the strength and the duration of the signal. If this is true, the search for LRRK2 interactors/effector proteins may be favoured by locking LRRK2 in a GTP-bound state, which is the active conformation for small GTPases and trimeric G-proteins.
LRRK2 substrates: still 'lurked'?
Protein kinases are ideal pharmacological targets. In cancer research, great therapeutic progress has been made towards the identification of selective inhibitors against up-regulated protein kinases, such as ErbB receptors in breast and lung carcinomas [23] . The facts that LRRK2 is a protein kinase and that the pathology of sporadic and LRRK2-linked PD is almost indistinguishable have led to a tremendous research and funding commitment to understand the role of LRRK2 kinase activity on PD onset and to design specific kinase inhibitors. Although more than 7 years have passed since the first evidence that mutations in LRRK2 cause PD, no convincing physiological substrates have yet been identified.
There is mounting evidence that LRRK2 may function as a scaffold to anchor cellular components (i.e. signal transduction complexes or organelles) to the cytoskeleton [24, 25] . In particular, several independent studies suggest that LRRK2 interacts with α-and β-tubulins, the building blocks of microtubules, and filamentous actin [24] [25] [26] [27] , and that LRRK2 activity influences neurite outgrowth [28] [29] [30] [31] . Interestingly, many of the proposed LRRK2 substrates are linked to cytoskeleton function. Jaleel et al. [9] were the first to report an in vitro substrate for LRRK2 from rat brain extracts. They found that LRRK2 phosphorylates moesin, a protein that anchors the actin cytoskeleton to the plasma membrane [9] . However, phosphorylation could be observed only after moesin pre-heating, which caused a partial unfolding of the C-terminal region of the protein where the LRRK2 phosphorylation site is located [9] . Although moesin is likely to be only an efficient in vitro substrate for LRRK2, it turned out to be very useful for designing peptide substrates (i.e. LRRKtide and Nictide) as alternatives to LRRK2 itself [9, 10] . Of interest, Parisiadou et al. [25] reported that the G2019S mutation enhances phosphorylation of ERM (ezrin/radixin/moesin) proteins in cultured neurons, indicating that, even though not directly, LRRK2 may influence the phosphorylation state of moesin with consequences for actin cytoskeletal dynamics and neurite growth [25] . It was also reported that LRRK2 can associated with and phosphorylate β-tubulin [27] , and this association seems crucial to mediate LRRK2-specific tau phosphorylation at Thr 181 [32] . Pathological mutations in the LRRK2 kinase domain increase tau phosphorylation in vitro [32] , whereas elevated phospho-tau has been observed in LRRK2 transgenic models [33] . Given that the levels of phosphorylated tau are dramatically increased in PD brains and that autoptic samples from PD individuals with mutations in LRRK2 occasionally display tau pathology [5] , an intriguing possibility is that LRRK2 acts upstream of tau in the neurodegenerative process. α-Synuclein is also abnormally phosphorylated in Lewy bodies and one study found LRRK2-mediated α-synuclein phosphorylation at Ser 129 [34] , although this observation is limited to this single study. Another controversial LRRK2 substrate is 4EBP1 (eukaryotic initiation factor 4E-binding protein 1), a negative regulator of protein translation [35] . Imai et al. [35] observed that LRRK2-dependent phosphorylation of 4EBP1 leads to increased protein translation with deleterious effects for dopaminergic neuron survival. However, another study could not observe robust LRRK2 phosphorylation of 4EBP1 in vitro, at least compared with other established kinases for 4EBP1 [36] , highlighting how 4EBP1 may not be a direct LRRK2 substrate.
At least two independent studies have shown robust phosphorylation of MKKs 3, 6 and 7 [21, 37] . Although the phosphorylation has been shown in vitro, it is interesting to speculate on a role for LRRK2 as a stress response kinase. The kinase domain of LRRK2 shares homology with RIPKs and MLKs (mixed lineage kinases) [7] . RIPKs mediate signalling through death receptors and activate stress kinases such as JNK. The JNK pathway is activated in mice treated with MPTP (1-methyl-4-phenyl-1,2,3 ,6-tetrahydropyridine) [8] , whereas the RIPK family is particularly interesting in that LRRK2 mediates signalling through the death receptor protein FBP (Fas-binding protein) [38] . Moreover, LRRK2 binds to JIPs, a group of scaffold proteins that play an important role in the regulation of MAPK (mitogen-activated protein kinase) signalling cascades [22] .
The lack of clear physiological LRRK2 substrates despite the significant commitment by the research community may indicate that LRRK2 activity is very low under basal conditions and that appropriate stimuli (i.e. stress or inflammation) are needed to activate the protein.
LRRK2 kinase inhibition: a therapeutic strategy?
At least six mutations with proven pathogenicity have been identified in the LRRK2 coding sequence (Figure 1) . What is still not clear is whether there is a common pathogenic mechanism for all mutations. The straightforward scenario where all mutations increase kinase activity has been disproven by experimental evidence from different laboratories (reviewed in [7] ). In fact, the only mutation that clearly has an activating effect is the G2019S mutation, which has been shown to increase kinase activity at least 3-fold [7] . Mutations in the ROC-COR domain (R1441C/G and Y1699C) decrease GTPase activity in vitro [39, 40] . One possibility is that GTPase activity is physiologically important and an increased time spent in the GTP-bound form results in sustained signalling. If autophosphorylation controls upstream GTPase function as discussed above, hyperautophosphorylation owing to the presence of the G2019S mutation may have downstream effects on GTP hydrolysis. In support of this model, Liu et al. [41] observed that G2019S-LRRK2 modestly decreases GTPase activity. Alternatively, it has been proposed that the ROC GTPase domain stimulates kinase activity [42] . In this model, ROC-COR mutations with lower GTPase activity could be hyperactivating mutations with respect to kinase activity. An additional scenario is that LRRK2 may have stopped functioning as a kinase long ago during evolution (which would explain the failure to identify substrates) and G2019S-LRRK2 represents a sort of reactivated protein. Of interest, Liu et al. [43] reported that the increased kinase activity of the G2019S mutant is substrate-dependent, suggesting the intriguing possibility that G2019S-specific substrates may exist.
Overall, the emerging picture is that the role of kinase activity in LRRK2-linked PD is still unclear. However, the observations that (i) mutant LRRK2 is toxic to neuronal cells only if kinase activity is present [44, 45] , and (ii) small inhibitors against LRRK2 are effective at rescuing LRRK2-mediated neurotoxicity [46] have prompted large efforts towards the discovery of specific inhibitors. A number of commercial kinase inhibitors, such as protein kinase C inhibitors, are effective at reducing LRRK2 activity [46] , as well as the potent ALK (anaplastic lymphoma kinase) inhibitor TAE684 which displays IC 50 values of 7 nM against LRRK2 [47] . In 2011, Deng et al. [48] reported the first potent and selective LRRK2 inhibitor (IN-1) , which they used to effectively abrogate LRRK2 activity in vivo. The compound, however, displays minimal ability to cross the blood-brain barrier, resulting in it being a useful tool only for in vitro studies.
The next key steps towards LRRK2 pharmacological inhibition are the identification of highly specific and potent small molecules against LRRK2 activity that are able to cross the blood-brain barrier and reach the regions of the brain that are selectively targeted in PD. One potential hurdle is that none of the LRRK2 murine models displays obvious neurodegenerative phenotypes, but only subtle defects in dopaminergic neurotransmission [33, [49] [50] [51] . Evaluating the effectiveness and the side effects of a compound without having a model with a clear-cut phenotype makes the task more difficult. Therefore the development of suitable experimental models to test whether inhibition of LRRK2 is the right therapeutic strategy against LRRK2-linked PD is of fundamental importance.
Given the role played by LRRK2 also in sporadic forms of PD, developing and testing the efficacy of LRRK2 inhibitors is of high priority for PD therapeutics.
